Apogee Therapeutics Inc. (APGE)
(Delayed Data from NSDQ)
$38.33 USD
+1.09 (2.93%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $38.28 -0.05 (-0.13%) 7:58 PM ET
2-Buy of 5 2
D Value F Growth C Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
APGE 38.33 +1.09(2.93%)
Will APGE be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for APGE based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for APGE
Wall Street Analysts See a 129.09% Upside in Apogee Therapeutics Inc. (APGE): Can the Stock Really Move This High?
Wall Street Analysts Think Apogee Therapeutics Inc. (APGE) Could Surge 132.72%: Read This Before Placing a Bet
APGE: What are Zacks experts saying now?
Zacks Private Portfolio Services
Wall Street Analysts Believe Apogee Therapeutics Inc. (APGE) Could Rally 134%: Here's is How to Trade
Other News for APGE
BTIG Increases Price Target for Apogee Therapeutics (APGE) to $115 | APGE Stock News
Apogee Therapeutics price target raised by $15 at BTIG, here's why
Gold Falls 1%; ProKidney Shares Spike Higher
Apogee Therapeutics: Funding Supports Best-In-Class Ambitions In Atopic Dermatitis
12 Health Care Stocks Moving In Monday's Intraday Session